Testing effectiveness (Phase 2)Study completedNCT01682213
What this trial is testing
Adjuvant Dabrafenib (GSK2118436) in Patients With Surgically Resected AJCC Stage IIIC Melanoma Characterized by a BRAFV600E/K Mutation
Who this might be right for
Melanoma
Memorial Sloan Kettering Cancer Center 23